GSK’s Benlysta claims first FDA okay for lupus kidney damage
pharmaphorum
DECEMBER 18, 2020
GlaxoSmithKline’s Benlysta has been on the market for almost a decade, but it still has some tricks up its sleeve – it’s just become the first and only FDA-approved treatment for lupus nephritis. Approval in lupus nephritis is expected to push the product above the $1 billion threshold and into blockbuster sales territory.
Let's personalize your content